Auro Laboratories Limited has formally notified the stock exchanges about an upcoming board meeting scheduled for February 05, 2026, to review and approve the company's quarterly financial performance. The pharmaceutical company's announcement comes as part of its regulatory compliance under SEBI listing requirements.

Board Meeting Agenda

The board meeting has been convened with specific objectives outlined for stakeholder transparency:

Trading Window Restrictions

The company has implemented strict trading restrictions in accordance with insider trading prevention protocols. These measures ensure compliance with securities regulations and protect market integrity.

Regulatory Compliance

The notification has been issued under Regulation 29(1)(a) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. This regulation mandates companies to inform stock exchanges about board meetings where financial results will be considered.

The communication was signed by Siddhartha Deorah, Whole Time Director (DIN: 00230796), ensuring proper authorization and accountability. The company has also made this information available on its official website at www.aurolabs.com for broader stakeholder access.

Market Information

The announcement was directed to BSE Limited, where the company's securities are listed under Security Code 530233. This formal communication ensures all market participants have equal access to material information that could impact trading decisions.

Auro Laboratories Limited , a pharmaceutical company based in Maharashtra, has announced a significant milestone in its operations. The company has successfully completed a World Health Organization (WHO) inspection at its Active Pharmaceutical Ingredients (API) manufacturing facility located in MIDC Tarapur, Maharashtra.

WHO-GMP Certification Details

The company has received a World Health Organization - Good Manufacturing Practices (WHO-GMP) Certificate from the Food & Drug Administration, Maharashtra. This certification is valid until September 30, 2028, covering the company's bulk drugs manufacturing operations at the Tarapur location.

Implications for Auro Laboratories

The WHO-GMP certification is a testament to Auro Laboratories' commitment to maintaining high standards in its manufacturing processes. This certification may potentially open up new opportunities for the company in the global pharmaceutical market, as it is often a prerequisite for entering certain international markets.

Company Background

Auro Laboratories Limited operates in the pharmaceutical sector, specializing in the manufacture of Active Pharmaceutical Ingredients. The company's manufacturing unit is located in MIDC Tarapur, Maharashtra, while its registered office is in Mumbai.

Market Impact

While the immediate market impact of this certification is not provided in the available data, such recognitions typically enhance a company's credibility and may positively influence its market position in the pharmaceutical industry.

Investors and stakeholders in Auro Laboratories Limited may want to monitor how this certification might translate into business growth and market opportunities for the company in the coming months and years.